Search | Clinical Trials Finder

Conditions: Fractures
Interventions: rhBMP-2/CPM; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 9
States / cities: Little Rock, Arkansas • Aurora, Colorado • Denver, Colorado + 6 more

Conditions: Acute Exacerbation of COPD
Interventions: Hemolung Respiratory Assist System, Invasive mechanical ventilation; Device
Lead sponsor: Alung Technologies; Industry
Eligibility: 40 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 32
States / cities: Sacramento, California • Denver, Colorado • Newark, Delaware + 28 more

Conditions: Rectal Cancer
Interventions: Epacadostat, Short-course radiation therapy, CAPOX chemotherapy, FOLFOX chemotherapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 4
States / cities: Orange, California • Boston, Massachusetts • Detroit, Michigan + 1 more

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 26
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 20 more

Conditions: Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Schizophrenia
Interventions: Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 35 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Ulcer of Lower Extremity
Interventions: PalinGen Flow Amniotic Tissue Allograft; Biological
Lead sponsor: Amnio Technology, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Carmichael, California • Castro Valley, California • Fresno, California + 4 more

Conditions: Kidney Transplantation
Interventions: anti-thymocyte globulin, Fludarabine, Cyclophosphamide, Total Body Irradiation, acetaminophen, diphenhydramine, methylprednisolone, bone marrow transplant, MESNA, mycophenolate mofetil, prednisone, filgrastim; Biological · Drug · Radiation
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions: Liposomal Cyclosporine A, standard of care; Drug
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: COVID-19
Interventions: PF-06650833, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Small Cell Lung Cancer Extensive Stage
Interventions: Gocatamig, I-DXd, Atezolizumab, Carboplatin, Etoposide, Rescue Medications; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Santa Rosa, California • Aurora, Colorado • Orlando, Florida + 10 more

Conditions: Adenovirus Infection
Interventions: Posoleucel, Placebo; Drug
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more

Conditions: Advanced Cancer, Metastatic Cancer
Interventions: T-DXd; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Miami, Florida • Durham, North Carolina

Conditions: Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions: Valproic Acid Solution, Isotonic saline solution; Drug
Lead sponsor: Westat; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Short Bowel Syndrome
Interventions: Teduglutide, SOC; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 10
States / cities: Los Angeles, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
Interventions: Lung ultrasound; Diagnostic Test
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 27 Weeks to 34 Weeks
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Breast Cancer
Interventions: Decision Aid (DA), Standard of Care (SOC); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: RYZ811, RYZ801; Diagnostic Test · Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 10 more

Conditions: Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Interventions: WTX-330; Drug
Lead sponsor: Werewolf Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: Upper Resp Tract Infection
Interventions: TEM-PCR URI Panel, SOC/Empiric Diagnosis; Diagnostic Test · Other
Lead sponsor: Diatherix Laboratories, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Athens, Alabama • Huntsville, Alabama

Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy; Drug · Procedure · Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 66 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more

Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Antiandrogen Therapy, Abiraterone Acetate, Prednisone, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetic Foot Ulcer
Interventions: NOX1416 and SOC, SOC (Standard of care); Drug · Procedure
Lead sponsor: NOxy Health Products, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Coral Gables, Florida + 9 more

Conditions: Prostatic Neoplasms
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 1,140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 70
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more

Search by objective public record fields.

A Study of rhBMP-2/CPM in Closed Fractures of the Humerus

Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration

A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma

TEM-PCR™ Prospective Clinical Utility Study

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)